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Abstract
Background: Routine cytomegalovirus (CMV) screening during pregnancy is not recommended in the United
States and the extent to which it is performed is unknown. Using a medical claims database, we computed rates of
CMV-specific testing among pregnant women.
Methods: We used medical claims from the 2009 Truven Health MarketScanW Commercial databases. We computed
CMV-specific testing rates using CPT codes.
Results: We identified 77,773 pregnant women, of whom 1,668 (2%) had a claim for CMV-specific testing. CMV-specific
testing was significantly associated with older age, Northeast or urban residence, and a diagnostic code for
mononucleosis. We identified 44 women with a diagnostic code for mononucleosis, of whom 14% had CMV-specific
testing.
Conclusions: Few pregnant women had CMV-specific testing, suggesting that screening for CMV infection during
pregnancy is not commonly performed. In the absence of national surveillance for CMV infections during pregnancy,
healthcare claims are a potential source for monitoring practices of CMV-specific testing.
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Background
Cytomegalovirus (CMV) is the most common congenital
viral infection in the United States and a leading cause
of congenital hearing loss and neurological disability [1].
CMV can be transmitted to the fetus when a CMV sero-
negative woman develops a primary CMV infection dur-
ing pregnancy, or from latent virus reactivation from
maternal CMV infection acquired prior to pregnancy or
re-infection with a new CMV strain during pregnancy.
The risk of CMV transmission to the fetus is higher
among pregnant women with primary infection com-
pared to those who were IgG positive prior to preg-
nancy, IgG positive at their first pregnancy visit, or IgM
positive with high IgG avidity and therefore presumed to
have non-primary infection (30-40% compared to
0.2-2%) [2]. Although vertical transmission is more likely
to occur as a result of maternal infections in the third
trimester, the rate of permanent sequelae from CMV is
lower among infants infected during the third trimester
than among infants born to mothers with primary CMV
infection in the first trimester [3,4]. In the United States,
approximately 42-50% of women 20–49 years of age are
CMV seronegative [5], and it is estimated that 27,000
primary CMV infections occur among pregnant women
each year [6].
Most CMV infections in immunocompetent persons
are asymptomatic or present with non-specific symp-
toms [7,8], with only a minority of persons experiencing
mononucleosis [8]. Diagnosis of CMV infection among
otherwise healthy adults generally relies on serologic
testing; proposed algorithms have included documenta-
tion of seroconversion or detection of CMV-specific
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IgM antibody in association with low IgG avidity [4].
However confirmation of CMV seroconversion during
pregnancy has practical challenges [9]. Demonstrating
seroconversion requires multiple blood draws over time
as CMV IgM testing alone is not adequately specific for
diagnosing primary infection. It does not allow for reli-
able determination of the timing of infection, and in the
case of a pregnant woman, does not provide information
on whether CMV infection occurred before or after the
start of pregnancy. IgG avidity may provide information
on a window of time during which primary infection
may have occurred; however, most commercial labora-
tories in the United States do not currently offer CMV
IgG avidity testing [10]. When primary maternal CMV
infection is diagnosed or suspected, additional diagnostic
testing, including PCR or viral culture of either amniotic
fluid or fetal blood and fetal ultrasound or magnetic res-
onance imaging, may allow for determination of whether
fetal infection has occurred.
There is currently no recommendation for routine
CMV screening during pregnancy by any professional
association or national public health authority [11,12]
and provider and public awareness of congenital CMV
infection is low [13-16]. An uncontrolled study sug-
gested that CMV hyperimmune globulin administered
during pregnancy may help reduce the risk of congenital
CMV infection [17] and additional data from controlled
clinical studies may inform future treatment options
[18-20]. The extent to which prenatal screening or diag-
nostic testing for CMV is occurring in the United States
is unknown and there is currently little information on
national practices around CMV testing during preg-
nancy. Identifying testing practices will provide useful
information to monitor future screening and prevention
programs. We used a large healthcare claims database to
explore current practices and rates of CMV testing
among pregnant women in the United States.
Methods
Data source
The Truven Health MarketScanW Commercial Databases
(Truven Health MarketScan Databases, Truven Health
Analytics, Ann Arbor, MI) are derived from insurance
claims for almost 40 million employees and their benefi-
ciaries in the United States [21]. We used outpatient and
inpatient claims data from the 2009 MarketScan Com-
mercial Claims and Encounters databases, including in-
formation on demographics, health plan membership,
International Classification of Diseases-9th revision, Clin-
ical Modification (ICD-9-CM) codes, and Current Pro-
cedural Terminology (CPT) codes. This study was
reviewed by the human subjects research coordinator at
the CDC and, as an analysis of secondary data without
personal identifiers, was determined not to require insti-
tutional review board review.
Study definitions
We defined pregnant women as women aged 15–44 years
enrolled for 365 days in 2009 with their first delivery code
[Appendix] identified during October-December 2009 in
order to ensure that enrollees’ medical claims for the en-
tire pregnancy were captured. The delivery date was
approximated using the date of the first claim with a de-
livery code. We assumed that pregnancies lasted for no
longer than 42 weeks and defined pregnancy-associated
claims as those occurring in the 42 weeks before the first
claim with a delivery code. We classified claims which oc-
curred during 0–13 weeks to be within the 1st trimester,
those within weeks 14–26 to be in the 2nd trimester, and
those within weeks 27–42 to be in the 3rd trimester. A
prenatal visit was defined as a medical claim with a code
consistent with prenatal care [Appendix]. Prenatal care
was defined as ≥2 prenatal visits in the 1st trimester or ≥1
global billing codes for prenatal care (CPT 59400, 59425,
59426, 59510, 59610) anytime during the pregnancy. We
defined CMV-specific testing as a claim for CMV IgG,
IgM, direct fluorescent testing (DFA), enzyme immu-
noassay (EIA), or polymerase chain reaction (PCR)
[Appendix]. Potential cases of CMV infection or disease
were defined as pregnant women with an ICD-9-CM code
for CMV disease (078.5); cases of infectious mononucle-
osis were defined as pregnant women with an ICD-9-CM
code for mononucleosis (075). Since mononucleosis is a
potential symptom and possible indication of maternal
CMV infection [8], we examined rates of pregnant women
with a diagnostic code for mononucleosis. Although infec-
tious mononucleosis is a clinical syndrome commonly
associated with primary Epstein-Barr virus infection dur-
ing or after second decade of life [22], adults with primary
CMV infection may also develop mononucleosis-like syn-
dromes [23]. Evidence of laboratory confirmation of CMV
infection was not included in the CMV case definition
because laboratory testing results were not available in the
MarketScan database. We defined urban residence based
on an enrollee’s Metropolitan Statistical Area (MSA)
status.
Statistical analysis
We computed frequencies of pregnant women with a
code for CMV disease and CMV-specific testing to
evaluate whether a pregnant woman had a diagnostic
code for CMV disease based on clinical assessment
alone, or also in combination with laboratory testing.
We performed Pearson Chi Square or Fisher’s exact test
to examine whether there was an association between
CMV-specific testing and age, region, residence in an
urban area, and diagnosis of infectious mononucleosis.
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Variables with a p-value <0.05 were considered signifi-
cant. The data were analyzed using SAS (version 9.2;
SAS Institute Inc, Cary, NC).
To better understand the possible sensitivity of the
2009 MarketScan Commercial databases for detecting
claims for CMV-specific laboratory testing, we calcu-
lated frequencies of pregnant women with ≥1 codes for
other laboratory tests that are recommended by the
American College of Obstetricians and Gynecologists to
be routinely performed during pregnancy [24]. These
sub-groups included pregnant women who had claims
for rubella, anemia, urine, glucose, syphilis, hepatitis B,
chlamydia, and HIV testing [Appendix]. Among these
women, we also calculated the frequency of pregnant
women with a code for CMV-specific testing.
Results
There were 77,773 deliveries that occurred among
MarketScan Commercial enrollees during October-
December 2009; 92% of these deliveries occurred in
women aged 20–39 years. Characteristics of these women
are shown in Table 1. Among these, 54,925 (71%)
pregnant women received prenatal care (≥2 prenatal-
coded claims in the 1st trimester or global billing code for
prenatal care).
There were 1,668 (2%) pregnant women with a code
for CMV-specific testing [Table 2], of whom 1,624 had a
code for CMV IgG or IgM testing, 62 had a code for
CMV PCR, 2 had a code for CMV DFA, and 2 had a
code for CMV EIA. Among the 1,624 pregnant women
with a code for CMV IgG or IgM testing, 72% had
codes for both CMV IgG and IgM testing, 25% for
CMV IgG testing alone, and 3% for CMV IgM testing
alone. Among the 1,668 pregnant women with a code
for CMV-specific testing conducted during pregnancy,
half (52%) had testing performed in the 1st trimester
[Table 2]. Rates of CMV-specific testing were higher
among older women, women living in the Northeast
or an urban area, and women with a diagnostic code
for mononucleosis [Table 3]. Only 44 (0.06%) preg-
nant women had a diagnostic code for mononucle-
osis; of these, 6 (14%) had a code for CMV-specific
testing.
To assess the sensitivity of the MarketScan database
in capturing CMV-specific testing during pregnancy, we
calculated frequencies of other routinely recommended
prenatal laboratory tests that are conducted for all preg-
nant women as part of standard prenatal care [Table 4].
There were 71,002 (91%) pregnant women with ≥1
codes for other routinely recommended laboratory tests
(i.e., rubella, anemia, urine, glucose, syphilis, hepatitis B,
Chlamydia, and HIV); among these women with claims
for these other laboratory tests, 1,660 (2.3%, range
1.5-4.2%) had CMV-specific testing [Table 4].
We identified 12 (0.02%) pregnant women with an
ICD-9-CM code for CMV disease among the 77,773
pregnant women. Four (33%) were aged 20–29 years and
8 (67%) were aged 30–39 years [Table 1]. Ten (80%) had
a code for CMV-specific testing performed during preg-
nancy, with half tested in the 1st trimester [Table 2].
None of the pregnant women with an ICD-9-CM code
for CMV had a diagnostic code for mononucleosis.
Discussion
This is the first study to examine rates of prenatal
CMV testing in the United States using national health-
care claims data. We found that the rate of claims for
CMV testing among privately-insured pregnant women
in 2009 was low (2%), which suggests that screening for
CMV infection during pregnancy is not commonly per-
formed. This finding is consistent with self-reported
data from physicians in which only 1-2% reported rou-
tinely screening their pregnant patients for CMV infec-
tion [13,25]. Among those who reported ever testing
for CMV during pregnancy, testing usually occurred in
Table 1 Characteristics of pregnant womena and
pregnant womena with a diagnostic code for CMV,
MarketScan 2009
Characteristic Pregnant womena Pregnant womena with
an ICD-9-CM diagnostic
code for CMV disease
# % # %
Age Group (years)
15-19 2,955 3.8% 0 0.0%
20-29 30,819 39.6% 4 33.3%
30-39 40,815 52.5% 8 66.7%
40-44 3,184 4.1% 0 0.0%
Urban Residence
No 10,592 13.6% 2 16.7%
Yes 67,181 86.4% 10 83.3%
Regionb
Northeast 9,674 12.5% 1 8.3%
North Central 21,206 27.3% 3 25.0%
South 34,781 44.8% 5 41.7%
West 11,970 15.4% 3 25.0%
Diagnostic Code for Infectious Mononucleosisc
No 77,729 99.9% 12 100.0%
Yes 44 0.1% 0 0.0%
Note: CMV, cytomegalovirus; ICD-9-CM, International Classification of Diseases-
9th revision, Clinical Modification.
aPregnant women defined as female enrollees who were 1) aged 15–44 years,
2) enrolled for the entire year in 2009, and 3) had a delivery code
(defined in Appendix) between October-December 2009.
bExcludes those pregnant women with other or unknown information on
region.
cA diagnosis of mononucleosis was defined by an ICD-9-CM code for
infectious mononucleosis (ICD-9-CM 075).
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response to detection of a fetal abnormality or patient
request for testing [13]. We did not expect to find evi-
dence of widespread prenatal screening for CMV
infection in the United States as there are no recom-
mendations for it at this time from professional
associations such as the American College of Obste-
tricians and Gynecologists [11,24]. In some European
countries and in Israel, prenatal testing for CMV is
more widely performed, even in the absence of
recommendations for routine screening [26,27]. We
found higher rates of testing among patients in our
study population with a diagnosis of mononucleosis, a
symptom potentially attributable to CMV infection,
but the rate of testing for CMV was only 14% even
in this high-risk group. Although CMV infection is
often asymptomatic, CMV infection should be consid-
ered as part of the differential diagnosis in pregnant
women who present with mononucleosis-like symp-
toms [13,22]. Understanding current obstetric CMV
testing practices is important for identifying baseline
testing practices, and, in the future, for monitoring
implementation of screening and prevention programs
as recommendations evolve.
Routine prenatal screening for CMV remains contro-
versial and has not been endorsed by any professional
organization or public health authority worldwide
[11,12,27]. Data on the effectiveness of treatments for
primary CMV infection in pregnancy are limited [4,20],
although results from initial studies of treatment with
CMV-specific hyperimmune globulin were promising
[17]. In a study performed in Italy, they found that only
1 out of 31 pregnant women (3%) with primary CMV in-
fection who received hyperimmune globulin gave birth
to an infant with CMV disease, compared to 7 out of 14
pregnant women (50%) with primary CMV infection
who did not receive hyperimmune globulin [17]. How-
ever, this was not a randomized controlled study and the
efficacy of treatment with hyperimmune globulin could
not be properly assessed. Data from randomized clinical
trials in Europe and the United States could provide evi-
dence needed for treatment of primary CMV infection
with hyperimmune globulin [18-20]. Given the limited
experience with CMV IgG avidity testing in clinical set-
tings in the United States, algorithms for CMV counsel-
ing and screening, and effective treatment options,
would need to be evaluated before routine prenatal
screening for primary CMV infection could be
recommended.
Another prenatal approach for prevention of congeni-
tal CMV is counseling of women to avoid exposures to
Table 2 Type of CMV testing and timing of CMV testing among pregnant womena and among pregnant womena with
a diagnostic code for CMV, MarketScan 2009
Pregnant womena with
CMV-specific testingb
Pregnant womena with an
ICD-9-CM diagnostic code for CMV
disease and CMV-specific testingb
N, 10N, 1,668
# % # %
Type of CMV-specific Testb
CMV PCR ONLY 17 1% 1 10%
CMV DFA ONLY 1 0% 0 0%
CMV Serology ONLY (CMV IgG, IgM, and EIA) 741 44% 5 50%
CMV PCR AND CMV Serology 8 0% 0 0%
CMV PCR AND Non-Specific Culture or PCR 24 1% 2 20%
CMV PCR, CMV Serology, AND Non-specific Culture or PCR 13 1% 0 0%
CMV DFA, CMV Serology, AND Non-Specific Culture or PCR 1 0% 0 0%
CMV Serology AND Non-specific Culture or PCR 863 52% 2 20%
Gestational Age when CMV-Specific Testing Conductedc
1st Trimester 863 52% 5 50%
2nd Trimester 395 24% 4 40%
3rd Trimester 410 24% 1 10%
Note: CMV, cytomegalovirus; ICD-9-CM, International Classification of Diseases-9th revision, Clinical Modification; PCR, polymerase chain reaction; IgG,
Immunoglobulin G; IgM, Immunoglobulin M; DFA, direct fluorescent testing; EIA, enzyme immunoassay.
aPregnant women defined as female enrollees who were 1) aged 15–44 years, 2) enrolled for the entire year in 2009, and 3) had a delivery code (defined in
Appendix) between October-December 2009.
bCMV-specific testing includes CMV IgG, CMV IgM, CMV DFA, CMV EIA, and CMV PCR testing.
cDate of first claim with a delivery code (defined in Appendix) was used to approximate delivery date in order to calculate the approximate age when the first
CMV-specific testing was done. We assumed that CMV-specific testing which occurred 0–13 weeks was within the 1st trimester, testing within weeks 14–26 to be
in the 2nd trimester, and testing within weeks 27–42 to be in the 3rd trimester. Pregnant women with testing that occurred before (<0 weeks) or after (≥43 weeks)
pregnancy were excluded.
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CMV during pregnancy for all pregnant women, regard-
less of their CMV serostatus. The American College of
Obstetricians and Gynecologists recommends counsel-
ing pregnant patients about thorough hand-washing
when around young children to reduce CMV transmis-
sion [11]. Some data suggest that pregnant women are
more likely to adopt and maintain practices to reduce
household exposure to CMV if they are aware of their
CMV seronegative status [28]. Routine determination of
CMV serostatus before or early in pregnancy may en-
hance patient education efforts directed at reducing ex-
posure to CMV during pregnancy to prevent maternal
infection and subsequent vertical transmission. Data
from a large prospective study in France reported that
seroconversion rates in pregnant women told of their
CMV seronegative status and counseled to adopt behav-
ioral measures to reduce CMV exposure were 0.2%,
significantly lower than estimated pre-intervention sero-
conversion rates in the study and expected rates for this
population [28,29]. However, adherence to recom-
mended preventative measures was not monitored and
the study did not use a randomized design because the
investigators deemed it unethical. Results of a survey of
obstetricians and gynecologists in 2007 found fewer than
half reported counseling their patients about preventing
CMV infection [13]. Fuller implementation of recom-
mendations for routine counseling and the addition of
screening for CMV serostatus during pregnancy as part
of risk reduction counseling in the United States would
require provider education. In addition, careful consider-
ation of the timing and reporting of such testing, as well
as wider availability of CMV IgG avidity testing and
standardization of commercial assays [10] would be
required such that pregnant women identified as sero-
positive could be managed with additional diagnostic
testing as appropriate.
There are a number of limitations to this study based
on medical claims reported for insurance reimburse-
ment purposes. We did not have access to laboratory
results and it is not possible to link MarketScan claims
data with medical records to validate our ascertainment
of CMV testing. There is no CPT code for CMV IgG
avidity testing and therefore we were unable to deter-
mine rates of IgG avidity testing. Claims data may
underestimate laboratory tests that were performed if
the provider failed to bill for the testing or it was not
reimbursed by the enrollee’s insurance plan. Rates of
CMV testing may be further underestimated in claims
data if providers bill for CMV testing as part of a
bundled claim for comprehensive prenatal care services
under global billing rather than with a CMV-specific
Table 3 Association between CMV-specific testinga by
selected factors, pregnant womenb, MarketScan 2009
Factor Pregnant womenb
Total # Tested % Tested p-Value
Age Group (years)
15-19 2,955 22 0.7% <0.001
20-29 30,819 519 1.7%
30-39 40,815 1,022 2.5%
40-44 3,184 105 3.3%
Urban Residence
No 10,592 65 0.6% <0.001
Yes 67,181 1,603 2.4%
Regionc
Northeast 9,674 628 6.5% <0.001
North Central 21,206 313 1.5%
South 34,781 579 1.7%
West 11,970 148 1.2%
Diagnostic Code for Infectious Mononucleosisd
No 77,729 1,662 2.1% <0.001
Yes 44 6 13.6%
Note: CMV, cytomegalovirus; PCR, polymerase chain reaction; IgG,
Immunoglobulin G; IgM, Immunoglobulin M; DFA, direct fluorescent testing;
EIA, enzyme immunoassay; ICD-9-CM, International Classification of Diseases-
9th revision, Clinical Modification.
aCMV-specific testing includes CMV IgG, CMV IgM, CMV DFA, CMV EIA, and
CMV PCR testing.
bPregnant women defined as female enrollees who were 1) aged 15–44 years,
2) enrolled for the entire year in 2009, and 3) had a delivery code (defined in
Appendix) between October-December 2009.
cExcludes those pregnant women with other or unknown information on
region.
dA diagnosis of mononucleosis was defined by an ICD-9-CM code for
infectious mononucleosis (ICD-9-CM 075).
Table 4 Rates of routinely recommended laboratory tests
for pregnant womena, and rates of CMV-specific testing
among pregnant womena with claims for routinely









Anemia testing 10,033 (13) 146 (1.5)
Glucose testing 54,989 (71) 1,228 (2.2)
Urine testing 54,947 (71) 1,311 (2.4)
Syphilis testing 65,047 (84) 1,613 (2.5)
Chlamydia testing 49,730 (64) 1,225 (2.5)
HIV testing 57,262 (74) 1,530 (2.7)
Hepatitis B testing 23,011 (30) 800 (3.5)
Rubella testing 15,546 (20) 650 (4.2)
Note: CMV, cytomegalovirus; PCR, polymerase chain reaction; IgG,
Immunoglobulin G; IgM, Immunoglobulin M; DFA, direct fluorescent testing;
EIA, enzyme immunoassay.
aPregnant women defined as female enrollees who were 1) aged 15–44 years,
2) enrolled for the entire year in 2009, and 3) had a delivery code (defined in
Appendix) between October-December 2009.
bCMV-specific testing includes CMV IgG, CMV IgM, CMV DFA, CMV EIA, and
CMV PCR testing.
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code. It seems unlikely however that CMV testing rates
among pregnant women are much higher than those we
report as we did not find substantially higher testing
rates even among pregnant women for whom claims for
other routine laboratory tests recommended during
pregnancy were captured in the MarketScan Commer-
cial database. It is unclear why rates of prenatal care for
this privately insured population were lower than
expected, especially for some routinely recommended
tests such as anemia, hepatitis B, and rubella testing.
Administrative claims data may not fully capture all
prenatal care services, and this may be partially due to
global billing. The MarketScan population is not repre-
sentative of the national population since the data
represents a large convenient sample primarily of indivi-
duals with private employer insurance, which accounts
for 56% of the US population in 2009 [30]. People with
employer-sponsored insurance are less likely to be low-
income or non-white than are uninsured or publicly-
insured people [31]. Separate MarketScan databases
exist with healthcare claims data for the Medicaid
population and it would be useful to examine CMV
testing rates in the population with publicly-financed
health insurance.
Conclusions
This study serves as a baseline for understanding clinical
awareness of and prenatal testing practices for CMV in
the United States. Based on assignment of an ICD-9-CM
code for CMV disease, we estimate the rate of CMV
diagnosis during pregnancy in this population to be
0.02%. While 1-7% of susceptible pregnant women are
estimated to develop CMV infection during pregnancy
in the United States [6,29], there are limited data on the
proportion of these infections that are symptomatic, lead
to a medical visit, or result in diagnosis. Future studies
may want to examine pregnant women with ultrasound
results showing fetal abnormalities and the rates of ma-
ternal and fetal CMV testing among this group. The
problem of maternal CMV infection during pregnancy
and subsequent vertical transmission that results in
neurologic impairments and hearing loss among chil-
dren remains silent, despite its substantial public health
burden [32]. There is currently no national surveillance
for CMV infection or disease among pregnant women
or infants and children. Healthcare claims and other ad-
ministrative databases can be used to monitor uptake of
medical services [33,34]. Use of these types of data are
advantageous since the information is computerized and
are available for large patient populations. As options for
CMV prevention, diagnosis and treatment during preg-
nancy expand, there will be a growing need to monitor
prenatal testing practices.
Appendix
Appendix table 5 includes a list of ICD-9-CM (Inter-
national classification of diseases, 9th revision, clinical
modification) and CPT (Current procedural termin-
ology) codes used for the study, including codes for
CMV laboratory testing, pregnancy delivery, prenatal
care, CMV diagnosis and CMV-related symptoms, and
laboratory tests recommended as part of routine pre-
natal care.
Table 5 List of international classification of diseases, 9th
revision, clinical modification (ICD-9-CM) and current
procedural terminology (CPT) codes
ICD-9-CM/CPT code(s) Code description
CMV Laboratory Testing
CPT 86644-5 CMV Antibody Testing
CPT 87271 CMV Direct fluorescent antibody
(DFA) Testing
CPT 87332 CMV enzyme immunoassay
CPT 87495-87497 CMV Infectious agent detection
by nucleic acid
(DNA or RNA)
CPT 87252, 87254 Non-specific virus isolation by
culture
CPT 83890–1, 83898, 83900–2,
83904–9, 83912, 87800-1
Non-specific molecular diagnostics
or infectious agent detection
(DNA or RNA)
Pregnancy Delivery
ICD-9-CM 650 Normal Delivery
ICD-9-CM 658.1-3 Premature rupture of membranes
or delayed delivery after
spontaneous, unspecified,
or artificial rupture of membranes
ICD-9-CM 659 Other indications for care or
intervention related to labor and
delivery, not elsewhere classified
ICD-9-CM 66x.x Complications of labor and
delivery
ICD-9-CM 67x.x Complications of Puerperium
(period right after delivery)
ICD-9-CM V24.0 Postpartum care and examination,
immediately after delivery
ICD-9-CM V27.x Outcome of delivery
ICD-9-CM 69.02, 69.52 Dilation and curettage or
aspiration curettage of uterus,
following delivery or abortion
ICD-9-CM 72.x-74.x Delivery procedures
CPT 01958, 01960–2, 01967-9 Anesthesia for delivery
CPT 59200 Insertion cervical dilator
CPT 59300 Episiotomy or vaginal repair
CPT 59400-59414 Vaginal Delivery
CPT 59510, 59514 Cesarean Delivery
CPT 59610, 59612, 59618, 59620 Delivery after previous cesarean
delivery
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CMV: Cytomegalovirus; ICD-9-CM: International Classification of Diseases, 9th
revision, Clinical Modification; CPT: Current Procedural Terminology;
PCR: Polymerase chain reaction; IgG: Immunoglobulin G;
IgM: Immunoglobulin M; DFA: Direct fluorescent antibody; EIA: Enzyme
immunoassay.
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Table 5 List of international classification of diseases, 9th
revision, clinical modification (ICD-9-CM) and current
procedural terminology (CPT) codes (Continued)
Prenatal Care
ICD-9-CM 64x.x Complications of pregnancy
ICD-9-CM V22.xx Normal pregnancy
ICD-9-CM V23.xx Supervision high-risk pregnancy
ICD-9-CM V72.42 Pregnancy examination or test,
positive result
ICD-9-CM 75.1 Diagnostic amniocentesis
ICD-9-CM 75.2 Intrauterine transfusion
ICD-9-CM 75.3 Other intrauterine operations on
fetus and amnion
CPT 59000 Amniocentesis, diagnostic
CPT 59001-59076 Antepartum services
CPT 59618 Routine obstetric care including
antepartum care, cesarean
delivery, and postpartum care,
following attempted vaginal
delivery after previous cesarean
delivery
CPT 59897 Unlisted fetal invasive procedure,
including ultrasound guidance
CPT 76801-76828 Obstetrical ultrasound
CPT 76941 Ultrasound guidance for fetal
transfusion or cordocentesis
CPT 76945 Ultrasound guidance for
chorionic villus sampling
CPT 76946 Ultrasound guidance for
amniocentesis
CPT 80055 Obstetric panel
CPT 82105-7 Serum alpha-fetoprotein
CPT 82143 Amniotic fluid scan
(spectrophotometric)
CPT 82731 Fetal fibronectin
CPT 83030, 83033 Fetal hemoglobin
CPT 83632 Human placental lactogen
CPT 83661-4 Fetal lung maturity assessment
CPT 84163 Pregnancy-associated plasma
protein-A
CPT 84702-3 Human chorionic gonadotropin
CPT 85460-1 Hemoglobin or rbcs, fetal,
for fetomaternal hemorrhage
CPT 88235 Tissue culture of amniotic fluid
or chorionic villus cells
CPT 88267 Chromosome analysis using
amniotic fluid or chorionic
villus cells
CPT 88269 In situ chromosome analysis for
amniotic fluid cells
CPT 59400, 59425, 59426,
59510, 59610
Global billing code for routine
prenatal obstetric care
CMV Diagnosis and CMV-Related Symptoms
ICD-9-CM 078.5 CMV Disease
ICD-9-CM 075 Infectious Mononucleosis
Table 5 List of international classification of diseases, 9th
revision, clinical modification (ICD-9-CM) and current
procedural terminology (CPT) codes (Continued)
Routinely Recommended Laboratory Tests
CPT 82947–8, 82950–2, 83036-7 Glucose Test
CPT 81007, 81020, 87086, 87088,
87070–1, 87073, P7001
Urine Culture
CPT 86592–3, 80055, 86781 Syphilis Test
CPT 3513F, 80074, 86704, 86706,
87340, 87341
Hepatitis B Test
CPT 3511F, 86631, 86632, 87110,
87270, 87320, 87485,
87486, 87487, 87490, 87491,
87492, 87810; ICD-9 V739
Chlamydia Test
CPT 86689, 86701, 86702, 86703,
87390, 87391, 87534,
87535, 87536, 87537, 87538,
87539, G0432, G0433, G0435
HIV Test
CPT 85013–4, 85018 Anemia: Blood count with
hematocrit, Blood count with
hemoglobin
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